Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

902.63 -13.68 (-1.49%)

Streaming Delayed Price Updated: 11:34 AM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

Today 10:27 EDT

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

March 25, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

March 25, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an...

Via StockStory

Topics Artificial Intelligence Intellectual Property

The Steel-Walled Resurgence: How Foreign Capital and Policy Are Powering a New U.S. Industrial Golden Age

March 25, 2026

The United States is currently witnessing a structural pivot of historic proportions, as the long-heralded "U.S. Industrial Renaissance" moves from a policy ambition to a tangible, factory-floor...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early...

Via MarketMinute

Topics Artificial Intelligence Economy

Is the Vanguard Dividend Appreciation ETF a Buy Now? ↗

March 25, 2026

This ETF has struggled so far this year.

Via The Motley Fool

Topics ETFs Regulatory Compliance

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

The Vanguard Fund That Can Turn $400 Per Month Into More Than $1.5 Million ↗

March 24, 2026

Even if you're starting with $0 today, you can still build up a million-dollar portfolio with regular monthly investments.

Via The Motley Fool

Topics ETFs Retirement

Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF ↗

March 24, 2026

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

Via The Motley Fool

Topics ETFs

Regional Bank Stock Up 33% as $3.7 Million Exit Tells a Different Story ↗

March 24, 2026

First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.

Via The Motley Fool

Topics Regulatory Compliance

The Great Divergence: Q1 2026 M&A Hits Record $813.3 Billion Amidst "K-Shaped" Recovery

March 24, 2026

As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 ↗

March 24, 2026

Eli Lilly will discontinue select insulin products in EU markets by Q2 2027, citing commercial reasons as regulators monitor supply impact.

Via Benzinga

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗

March 24, 2026

The company recently obtained approval for a higher-dose version of Wegovy.

Via The Motley Fool

Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark

March 23, 2026

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026....

Via MarketMinute

Topics ETFs Earnings

$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today ↗

March 23, 2026

Via Benzinga

The Earnings Fortress: S&P 500 Defies 'Permacrisis' with Fifth Consecutive Quarter of Double-Digit Growth

March 23, 2026

As of March 23, 2026, the American corporate engine has proven itself to be remarkably high-revving, even as the global landscape shifts beneath it. Despite a volatile start to the year characterized...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

What's Going On With Eli Lilly On Monday? ↗

March 23, 2026

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks.

Via Benzinga

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

March 23, 2026

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Here's How Much Upside Eli Lilly Stock Has, According to Analysts ↗

March 23, 2026

Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

Via The Motley Fool

The Best Stocks to Invest $1,000 in Right Now ↗

March 23, 2026

Buying $1,000 of each of these stocks should pay off nicely over the long run.

Via The Motley Fool

Topics Artificial Intelligence

1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

March 23, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 22, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

VIG vs NOBL: Which Dividend ETF Should You Buy Now? ↗

March 22, 2026

Explore how each ETF’s unique sector focus and fee structure could impact your dividend strategy and long-term portfolio mix.

Via The Motley Fool

Topics ETFs

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Eli Lilly Stock Before April 10? ↗

March 22, 2026

A catalyst for stock performance may be just ahead.

Via The Motley Fool

Is This Stock a Buy on the Dip? ↗

March 21, 2026

This company has a habit of beating the market over long periods.

Via The Motley Fool

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Buyer’s Remorse: Why the Early-Week Market Rally Collapsed into a Flight for Safety

March 20, 2026

The promise of a mid-March market recovery vanished this week as a short-lived "relief rally" gave way to a wave of "buyer’s remorse," leaving investors scrambling for cover. What began on Monday as a...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks to Buy Before They Get Bought Out ↗

March 20, 2026

Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.